Ambrx Biopharma Cayman, Inc. Quarterly Retained Earnings (Accumulated Deficit) in USD from Q4 2020 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Ambrx Biopharma Cayman, Inc. quarterly Retained Earnings (Accumulated Deficit) history and growth rate from Q4 2020 to Q2 2023.
  • Ambrx Biopharma Cayman, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending June 30, 2023 was -$325M, a 22.5% decline year-over-year.
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2023 -$325M -$59.6M -22.5% Jun 30, 2023 10-Q 2023-08-09
Q1 2023 -$307M Mar 31, 2023 10-Q 2023-05-11
Q4 2022 -$292M -$78M -36.5% Dec 31, 2022 10-Q 2023-08-09
Q2 2022 -$265M Jun 30, 2022 6-K 2022-08-29
Q4 2021 -$214M -$68.1M -46.8% Dec 31, 2021 10-K 2023-03-30
Q4 2020 -$146M Dec 31, 2020 20-F 2022-04-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.